Blog
RSS FeedPosted by Michael Wonder on 22 Jan 2021
ICER releases draft evidence report on therapies for lupus nephritis
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 17 Dec 2020
ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
Posted by Michael Wonder on 22 Nov 2020
ICER publishes final report and policy recommendations for haemophilia A therapies
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...
Posted by Michael Wonder on 12 Nov 2020
ICER releases draft evidence report on treatments for high cholesterol
12 November 2020 - Public comment period on preliminary draft now open until 11 December 2020; requests to make oral comment ...
Posted by Michael Wonder on 06 Nov 2020
ICER publishes evidence report on new therapies for bladder cancer
6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...
Posted by Michael Wonder on 06 Nov 2020
ICER publishes evidence report on digital therapeutics for opioid use disorder
6 November 2020 - The available evidence on the benefits of reSET-O, Connections, and DynamiCare has substantial limitations and can ...
Posted by Michael Wonder on 18 Oct 2020
ICER publishes final report and policy recommendations for targeted immune modulator therapies for ulcerative colitis
16 October 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of vedolizumab over adalimumab. ...
Posted by Michael Wonder on 17 Oct 2020
ICER publishes evidence report on therapies for haemophilia A
16 October 2020 - Emicizumab assessed as providing comparable or better clinical benefits when compared to common current dosing levels of ...
Posted by Michael Wonder on 28 Sep 2020
ICER publishes white paper on cornerstones for fair patient access to prescription drugs, launches annual assessment of US payer policies
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper ...
Posted by Michael Wonder on 11 Sep 2020
ICER publishes evidence report on targeted immune modulator therapies for ulcerative colitis
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels ...
Posted by Michael Wonder on 31 Aug 2020
ICER posts draft scoping document on lupus nephritis
31 August 2020 - Document open to public comment until 21 September 2020. ...
Posted by Michael Wonder on 21 Jul 2020
ICER publishes evidence report on obeticholic acid for the treatment of non-alcoholic steatohepatitis
21 July 2020 - Given the FDA’s recent decision to not grant accelerated approval for the treatment, ICER has canceled its ...
Posted by Michael Wonder on 19 Mar 2020
ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis
19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...
Posted by Michael Wonder on 13 Mar 2020
ICER releases evidence report on treatments for sickle cell disease
12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...
Posted by Michael Wonder on 25 Feb 2020
ICER issues final report and policy recommendations on acute treatments for migraine
25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...